Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 2/20 | 0.44 |
| ▸ | CCNH | P51946 | 2/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | ULK1 | O75385 | 2/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569953 | 0.82 | LMNA (0.45) | LMNAHDAC6KCNN3ADRA2AADRA2B | |
| SCHEMBL2570647 | 0.80 | HDAC6 (0.46) | IGF1RLMNAHDAC6KCNN3ADRA2A | |
| SCHEMBL23804868 | 0.79 | ULK1 (0.39) | IGF1RCDK7CCNHMNAT1CCNE1 | |
| SCHEMBL14208456 | 0.77 | DHFR (0.53) | IGF1RLMNAHDAC6KCNN3ADRA2A | |
| SCHEMBL23804859 | 0.77 | CCNK (0.38) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL18425323 | 0.76 | ULK1 (0.39) | CCNE1CDK2ULK1 | |
| SCHEMBL23804863 | 0.76 | CCNK (0.38) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL1552289 | 0.76 | LMNA (0.51) | IGF1RLMNAHDAC6KCNN3ADRA2A | |
| SCHEMBL3205734 | 0.76 | LMNA (0.51) | IGF1RLMNAHDAC6KCNN3ADRA2A | |
| SCHEMBL1551936 | 0.76 | LMNA (0.51) | IGF1RLMNAHDAC6KCNN3ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384321-B1 | PYRIMIDINE DERIVATIVES AND USE THEREOF FOR COMBATING UNDESIRED PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-8329717-B2 | Pyrimidine derivatives and their use for controlling undesired plant growth | BAYER CROPSCIENCE AG (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-2384321-A1 | PYRIMIDINE DERIVATIVES AND THE USE THEREOF FOR COMBATING UNDESIRED PLANT GROWTH | Bayer CropScience AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| EP-2210879-A1 | Pyrimidine derivatives and use thereof for combating undesired plant growth | Bayer CropScience AG (DE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010076010-A1 | PYRIMIDINE DERIVATIVES AND THE USE THEREOF FOR COMBATING UNDESIRED PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2010-07-08 | — | — | WO | disclosed |
| US-20100167934-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH | BAYER CROPSCIENCE AG (DE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100167934-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH | TYMS, TYMP, UMPS | IGF1R 3783/4885LMNA 3961/4885CDK7 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.